A unique collaboration between electrical engineers, mechanical engineers and cancer researchers may be the perfect combination to improve diagnosis, treatment and follow-up of patients with melanoma.
Researchers at the University of Colorado Cancer Center, the University of Colorado at Boulder and the University of Texas at Dallas have received funding to develop a mechanical system the size of a wristwatch that will display the presence or absence of genetic signals of melanoma. The $1.1 million grant, funded over the next four years, was awarded by the National Science Foundation.
Engineers, working with cancer researchers, will use the funding attempt to "wire" and color code various genes using nanotechnology to screen blood samples. The goal is to help physicians and patients visualize changes that occur in melanoma cells that indicate important developments such as disease progression or response to therapy.
The development of a panel of melanoma-specific tumor markers through nanotechnology would significantly impact the way melanoma is diagnosed and treated because the tumor markers could be detected before a tumor had grown large enough to be detected using current imaging technology. Approximately 20 percent of patients who develop malignant melanoma die of metastases present at diagnosis but not detectable by any current imaging or biochemical techniques. Determination of who has, or will develop, cancer is an important step in the diagnosis, follow up and treatment of cancer.
Nanomachines can be engineered to sense and pick up molecular markers of cancer cells, enabling scientists to detect molecular changes even when they occur only in a small percentage of cells. The nanoparticles are used to detect the presence of genetic changes and relay the information via electrical connections to doctors and researchers. The connections will produce different colors for different biomarkers.
"Imagine going to your doctor, and with a device the size of a wristwatch, being able to know within five minutes whether or not certain molecular signs of melanoma are present in a blood sample," said Lynne Bemis, PhD, associate professor at UCCC and a lead researcher on the grant. "By 'seeing' at the very basic level if key biomarkers for melanoma are present and in what capacity, patients and their physicians will have valuable information about cell changes much earlier than current screening technologies do."
Bemis added that a nano device has the potential to not only show changes sooner than current technologies, such as PET (Positron Emission Tomography) Scanning, but would also be cost effective and more efficient. She emphasized that the device is years from its clinical debut, but this grant funding enables researchers to lay the groundwork that is critical to making the device a reality.
"From the engineer's point of view, nanotechnology is very exciting because it enables us to perform a variety of manipulations and operations directly at the size scale of the molecules linked to the disease. Better understanding the interaction of nanomaterials with various biomolecules will open doors to radically new ways to detect and intervene in disease processes," said Won Park, PhD, assistant professor at the University of Colorado at Boulder and the principal investigator of the grant.
Bemis and researchers in the William Robinson lab at the Anschutz Medical Campus in Aurora, Colo., have already identified several biomarkers for Park to build into the panel and color code in collaboration with Jeong-Bong Lee, PhD, associate professor at the University of Texas at Dallas. The UCCC researchers will continue to look for novel biomarkers so that the engineers in Boulder and Dallas can develop a truly comprehensive panel that will provide the most complete information about each patient's tumor. More information on this project can be found at the project's Web site,
http://onchip.colorado.edu .
Source: University of Colorado
Related stories:
The genetics of the white horse unraveled
The white horse is an icon for dignity which has had a huge impact on human culture across the world. An international team led by researchers at Uppsala University has now identified the mutation causing this spectacular trait and show that white horses carry an identical mutation that can be traced back to a common ancestor that lived thousands of years ago. The study is interesting for medical research since this mutation also enhance the risk for melanoma. The paper is published on July 20 on the website of
Nature Genetics.
As rates rise, researchers find better way to identify melanoma
University of Rochester Medical Center researchers found a new protein produced excessively in malignant melanoma, a discovery that is particularly relevant as skin cancer rates climb dramatically among young women.
Nanomaterials Key to New Strategies for Blocking Metastasis
A new treatment strategy using targeted nanoparticles to block metastasis with anti-cancer drugs leads to good results using significantly lower doses of toxic chemotherapy, with less collateral damage to surrounding tissue, according to a collaborative team of researchers at the Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego. In designing this system, the investigators, led by David Cheresh, Ph.D., have identified what may become a generic method for using nanotechnology to target metastasis.
Analysis of cancer incidence, mortality and survival combined reveals encouraging European trends
The first research to look at recent trends in European cancer incidence, mortality and survival together has shown that cancer prevention and management in Europe is moving in the right direction. However, the research reveals that variations between countries in policies for mass screening, access to health care and treatment are reflected in the different cancer rates.
Discovery of gene mechanism could bring about new ways to treat metastatic cancer
Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.
Overcoming Drug Resistance—Nanoparticles Trigger Built-In Cell-Death Signal
One of the most vexing problems in treating cancer is the propensity of tumors to develop resistance to a wide range of anticancer drugs. Over 70 percent of ovarian cancer patients, for example, have drug-resistant tumors at the time of their initial diagnosis, and virtually all patients who relapse have drug-resistant tumors.
Combination therapy packs 1-2 punch against melanoma
Disabling a protein frequently found in melanoma tumors may make the cancer more vulnerable to chemotherapy, according to a pilot study led by researchers in the Duke Comprehensive Cancer Center.
New combination therapy safe, promising for melanoma patients
The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.